Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya8298110.26442/00403660.2021.09.201023ReviewsОбзорыResearch ArticleInfluenza vaccination and prognosis for patients with high cardiovascular riskВакцинация против гриппа и прогноз пациентов с высоким сердечно-сосудистым рискомhttps://orcid.org/0000-0001-9240-9513DmitrievaOlga A.ДмитриеваОльга Александровна
Russian Federation

клин. ординатор каф. факультетской терапии №1 лечебного фак-та

olga.dm.ru@mail.ruhttps://orcid.org/0000-0002-5820-1759MironovaOlga Iu.МироноваОльга Юрьевна
Russian Federation

канд. мед. наук, доц. каф. факультетской терапии №1 лечебного фак-та

olga.dm.ru@mail.ruhttps://orcid.org/0000-0002-2682-4417FominVictor V.ФоминВиктор Викторович
Russian Federation

чл.-кор. РАН, д-р мед. наук, проф., проректор по клинической работе и ДПО, зав. каф. факультетской терапии №1 лечебного фак-та

olga.dm.ru@mail.ruSechenov First Moscow State Medical University (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)15092021939110011051010202110102021Copyright ©; 2021, Consilium MedicumCopyright ©; 2021, ООО "Консилиум Медикум"2021Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/82981

Cardiovascular and respiratory diseases have been one of the leading causes of mortality in the world for over 15 years. According to the results of various studies, a clear connection was revealed between the incidence of influenza and the decompensation of cardiovascular diseases, which leads to the development of acute coronary syndrome, acute heart failure and myocardial infarction. Also, the incidence of influenza is associated with an increase in the length of hospitalization, treatment costs and patient mortality. Influenza vaccination, especially in patients with high cardiovascular risk, is one of the most important secondary prevention measures. The article is dedicated to an overview of the problems of vaccination against influenza, the study of the prognosis of patients with high cardiovascular risk, as well as general points in the pathogenesis of influenza and cardiovascular diseases.

Сердечно-сосудистые и респираторные заболевания занимают одни из лидирующих позиций среди причин смертности населения в мире более 15 лет. По результатам разных исследований выявлена четкая взаимосвязь между заболеваемостью гриппом и декомпенсацией сердечно-сосудистых заболеваний, что ведет к развитию острого коронарного синдрома, острой сердечной недостаточности и инфаркта миокарда. Также заболеваемость гриппом связана с увеличением продолжительности госпитализации, расходов на лечение и смертности пациентов. Вакцинация против гриппа, особенно у пациентов с высоким сердечно-сосудистым риском, является одной из важнейших мер вторичной профилактики. Статья посвящена обзору проблем вакцинации против гриппа, изучению прогноза пациентов с высоким сердечно-сосудистым риском, а также общим моментам в патогенезе гриппа и сердечно-сосудистых заболеваний.

cardiovascular diseasesinfluenzacardiovascular riskacute coronary syndromemyocardial infarctioninfluenza vaccinationсердечно-сосудистые заболеваниягриппсердечно-сосудистый рискострый коронарный синдроминфаркт миокардавакцинация против гриппаWarren-Gash C, Blackburn R, Whitaker H, et al. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018;51(3):1701794. DOI:10.1183/13993003.01794-2017Graham-Rowe D. Epidemiology: Racing against the flu. Nature. 2011;480(7376):S2-3. DOI:10.1038/480S2aVardeny O, Udell JA, Joseph J, et al. High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. Am Heart J. 2018;202:97-103. DOI:10.1016/j.ahj.2018.05.007For Europe WHORO. WHO Regional Office for Europe recommendations on influenza vaccination for the 2020/2021 season during the ongoing COVID-19 pandemic. World Health Organization. Regional Office for Europe; 2020.Клинические рекомендации. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. 2020. Режим доступа: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_sST.pdf. Ссылка активна на 24.08.2021 [Clinical guidelines. Acute myocardial infarction with ST segment elevation on electrocardiogram. 2020. Available at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_sST.pdf. Accessed: 24.08.2021 (in Russian)].Клинические рекомендации. Острый инфаркт миокарда без подъема сегмента ST электрокардиограммы. 2020. Режим доступа: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST.pdf. Ссылка активна на 24.08.2021 [Clinical guidelines. Acute myocardial infarction without ST segment elevation on electrocardiogram. 2020. Available at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST.pdf. Accessed: 24.08.2021 (in Russian)].Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367. DOI:10.1093/eurheartj/ehaa575Ciszewski A. Cardioprotective effect of influenza and pneumococcal vaccination in patients with cardiovascular diseases. Vaccine. 2018;36:202-6. DOI:10.1016/j.vaccine.2017.11.078Muscente F, de Caterina R. Causal relationship between influenza infection and risk of acute myocardial infarction: pathophysiological hypothesis and clinical implications. Eur Heart J. 2020;22(Suppl. E): E68-72. DOI:10.1093/EURHEARTJ/SUAA064Luan YY, Yao YM. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Front Immunol. 2018;9:1-8. DOI:10.3389/fimmu.2018.01302Garraud O, Kehrel BE, Badimon L, et al. C-Reactive Protein in Atherothrombosis and Angiogenesis. Frontiers in Immunology. Frontiers Media S.A. 2018;9:430. DOI:10.3389/fimmu.2018.00430Tripathi B, Kumar V, Kalra A, et al. Influence of Influenza Infection on In-Hospital Acute Myocardial Infarction Outcomes. Am J Cardiol. 2020;130:7-14. DOI:10.1016/j.amjcard.2020.05.045Cardoso R, Rivera M, Czarny MJ, et al. In-Hospital Management and Outcomes of Patients With Acute Myocardial Infarction and Influenza. Am J Cardiol. 2020;125(6):840-4. DOI:10.1016/j.amjcard.2019.12.032Smeeth L, Thomas SL, Hall AJ, et al. Risk of Myocardial Infarction and Stroke after Acute Infection or Vaccination. N Engl J Med. 2004;351(25):2611-8. DOI:10.1056/nejmoa041747Gurfinkel EP, Leon De La Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study: One-year follow-up. Eur Heart J. 2004;25(1):25-31. DOI:10.1016/j.ehj.2003.10.018Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 2000;102(25):3039-45. DOI:10.1161/01.CIR.102.25.3039Meyers DG, Beahm DD, Jurisich PD, et al. Influenza and pneumococcal vaccinations fail to prevent myocardial infarction. Heart Drug. 2004;4(2):96-100. DOI:10.1159/000077705Heffelfinger JD, Heckbert SR, Psaty BM, et al. Influenza vaccination and risk of incident myocardial infarction. Hum Vaccin. 2006;2(4):161-6. DOI:10.4161/hv.2.4.2943Puig-Barberà J, Díez-Domingo J, Varea ÁB, et al. Effectiveness of MF59TM-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine. 2007;25(42):7313-21. DOI:10.1016/j.vaccine.2007.08.039Siriwardena AN, Gwini SM, Coupland CAC. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: Matched case – Control study. CMAJ. 2010;182(15):1617-23. DOI:10.1503/cmaj.091891Warren-Gash C, Geretti AM, Hamilton G, et al. Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza A H1N1 pandemic in London: A case-control study. BMJ Open. 2013;3(5):1-7. DOI:10.1136/bmjopen-2013-002604MacIntyre CR, Heywood AE, Kovoor P, et al. Ischaemic heart disease, influenza and influenza vaccination: A prospective case control study. Heart. 2013;99(24):1843-8. DOI:10.1136/heartjnl-2013-304320Hsu SY, Chen FL, Liaw YP, et al. A matched influenza vaccine strain was effective in reducing the risk of acute myocardial infarction in elderly persons: A population-based study. Med (United States). 2016;95(10):1-6. DOI:10.1097/MD.0000000000002869Barnes M, Heywood AE, Mahimbo A, et al. Acute myocardial infarction and influenza: A meta-analysis of case-control studies. Heart. 2015;101(21):1738-47. DOI:10.1136/heartjnl-2015-307691Karaulov AV, Bykov AS, Volkova NV. Review of Grippol Family Vaccine Studies and Modern Adjuvant Development. Epidemiol Vaccinal Prev. 2019;18(4):101-19. DOI:10.31631/2073-3046-2019-18-4-101-119Wu HH, Chang YY, Kuo SC, Chen YT. Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders – A propensity score-matched follow-up study. PLoS One. 2019;14(7):e0219172. DOI:10.1371/journal.pone.0219172Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to Lipid-lowering Therapy and the Use of Preventive Health Services: An Investigation of the Healthy User Effect. Am J Epidemiol. 2007;166(3):348-54. DOI:10.1093/aje/kwm070Shrank WH, Patrick AR, Brookhart MA. Healthy User and Related Biases in Observational Studies of Preventive Interventions: A Primer for Physicians. J Gen Intern Med. 2010;26(5):546-50. DOI:10.1007/s11606-010-1609-1Madjid M, Awan I, Ali M, et al. Influenza and atherosclerosis: Vaccination for cardiovascular disease prevention. Expert Opin Biol Ther. 2005;5(1):91-6. DOI:10.1517/14712598.5.1.91Shah AM, Pfeffer MA, Hartley LH, et al. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am J Cardiol. 2010;106(7):911-6. DOI:10.1016/j.amjcard.2010.05.021Critchley JA, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2012;(2):1465-858. DOI:10.1002/14651858.CD003041.pub3Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. DOI:10.1016/S0140-6736(10)61350-5Sheng X, Wei L, Murphy MJ, MacDonald TM. Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: Results from a meta-analysis and an observational study. Eur J Clin Pharmacol. 2009;65(11):1071-80. DOI:10.1007/s00228-009-0720-xFerrari R, Bertrand ME, Remme WJ, et al. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: The EUROPA trial. Expert Rev Cardiovasc Ther. 2007;5(6):1037-46. DOI:10.1586/14779072.5.6.1037England TN. Effect of Ramipril on Cardiovascular Events in High-Risk Patients. N Engl J Med. 2000;343(1):64-6. DOI:10.1056/nejm200007063430113MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016;102(24):1953-6. DOI:10.1136/heartjnl-2016-309983Shalnova SA, Deev AD. Russian mortality trends in the early XXI century: Official statistics data. Cardiovasc Ther Prev. 2011;10(6):5-10. DOI:10.15829/1728-8800-2011-6-5-10Goldsteyn EM. Influenza-associated mortality for circulatory and respiratory causes during the 2013–2014 through the 2018–2019 influenza seasons in Russia. Int J Appl Fundam Res. 2019;12:9-16. DOI:10.17513/mjpfi.12945Vardeny O, Madjid M, Solomon SD. Applying the Lessons of Influenza to COVID-19 During a Time of Uncertainty. Circulation. 2020;141(21):1667-9. DOI:10.1161/CIRCULATIONAHA.120.046837